Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III extension study of jaketinib hydrochloride tablets for long-term safety and efficacy in moderate-to-severe atopic dermatitis
CTR20223203Phase 3Active
- Sponsor
- Zelgen
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of jaktinib in atopic dermatitis (AD), sponsored by Zelgen. Started Jan 2023; status: active.
02
Drugs
jaktinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20223203.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223203.